Prof. Roger Schibli

Head of the Centre for Radiopharmaceutical Sciences, ETH Zurich

Prof. Roger Schibli is a Laboratory Head at Biology and Chemistry Division (BIO) and professor at the ETH Zürich since 2004. He is leading the Center for Radiopharmaceutical Science (CRS), a joint endeavor between the ETH Zurich, the Paul Scherrer Institute, and the University Hospital Zurich. Prof. Schibli studied Chemistry at the University of Basel. His early research was dedicated to the development of new organometallic complexes of technetium and rhenium for medical application. He spent two years at the University of Missouri-Columbia as a post-doctoral fellow. Prof. Schibli's research is directed towards targeted tumor diagnosis and therapy using radiolabeled compounds. His lab focuses on the development of new radionuclides, identification of novel targeting molecules, and their biological and pharmacological characterization and optimization. CRS performs “bench-to-bedside” research and has the capacity to translated novel radiopharmaceutical drug candidates into clinical testing. A 177Lu-labeled peptide developed in his lab was recently licensed to Debiopham™. Besides, Prof. Schibli is a co-founder of the spin-off company ARARIS Biotech, developing antibody-drug-conjugates.